Canada markets closed

ImmuCell Corporation (IUL.F)

Frankfurt - Frankfurt Delayed Price. Currency in EUR
Add to watchlist
4.8000+0.0800 (+1.69%)
At close: 08:00AM CEST
Full screen
Previous Close4.7200
Open4.8000
Bid4.8200 x 300000
Ask5.0000 x 300000
Day's Range4.8000 - 4.8000
52 Week Range4.0600 - 5.4000
Volume60
Avg. Volume28
Market Cap38.859M
Beta (5Y Monthly)0.61
PE Ratio (TTM)N/A
EPS (TTM)-0.7000
Earnings DateMay 14, 2024
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • GlobeNewswire

    ImmuCell to Announce Unaudited Financial Results for the Quarter Ended March 31, 2024

    Conference Call Scheduled for Wednesday, May 15, 2024 at 9:00 AM ETPORTLAND, Maine, May 08, 2024 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, expects to report unaudited financial results for the quarter ended March 31, 2024 after the market closes on Tuesday, May 14, 2024.

  • GlobeNewswire

    ImmuCell Announces Preliminary, Unaudited Sales Results for Q1 2024

    PORTLAND, Maine, April 09, 2024 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, today announced preliminary, unaudited sales results for the first quarter of 2024, which ended March 31, 2024. Preliminary, Unaudited Total Sales Results: 20242023$ Increase % IncreaseDuring the T

  • Insider Monkey

    ImmuCell Corporation (NASDAQ:ICCC) Q4 2023 Earnings Call Transcript

    ImmuCell Corporation (NASDAQ:ICCC) Q4 2023 Earnings Call Transcript February 28, 2024 ImmuCell Corporation isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good morning and welcome to the ImmuCell Corporation reports Fourth Quarter and Year Ended December 31, 2023 Unaudited Financial […]